Results 131 to 140 of about 4,662,895 (269)

Design of and Early Insights From a Generalized Myasthenia Gravis Patient Engagement Research Council

Health Science Reports
Background and Aims An exploratory focus group study was conducted to better understand the needs of patients living with generalized myasthenia gravis (gMG).
Gabrielle Geonnotti, Jacqueline Pesa, Wesley Peters, Melina Taylor, Zia Choudhry, Oluyemisi Falope, Marquetta Price, Lucy Baxter, Bruce West, Lisa Shea   +9 more
doaj   +1 more source

From patient advocacy to patient‐driven research: Building active partnerships beginning at the bench to reach the bedside

FEBS Open Bio, EarlyView.
Research is strongest when conducted alongside patients, not just about them. Patient research organizations help integrate patient perspectives into research priorities, study design, and scientific meetings, leading to meaningful patient outcomes and development of relevant therapies.
Jenica H. Kakadia, Rachel Heilmann, Maximiliano Barrientos, Laura MacNeill, Ingrid Vallee, Sarah K. Schultz, Patrick O'Donoghue, Angelica A. Moresco, Victoria M. Siu, Ilka U. Heinemann   +9 more
wiley   +1 more source

Cell surface CD11c as a neutrophil aging marker molecule

FEBS Open Bio, EarlyView.
Cell surface CD11chi neutrophils were more aged and had better phagocytic function than CD11c−/lo neutrophils. Transcriptomic analysis of CD11chi neutrophils and CD11c−/lo neutrophils in pediatric population showed that the most difference was seen in infants.
Sophia Koutsogiannaki, Fahd Alhamdan, Erik Malm, Marie Bermudez, Samuel Y. Kim, Koichi Yuki   +5 more
wiley   +1 more source

Shifting power: co-developing a framework for equity in healthcare

BMC Health Services Research
Background Efforts to advance equity, diversity, and inclusion (EDI) in healthcare have grown quickly in recent years, spurred by the broader calls to confront systemic racism and address structural inequities exposed during the COVID-19 pandemic.
Sumaya Mehelay, Brady Comeau, Shivani Chandra, Carol Fancott, Dara Gordon, Kent Cadogan Loftgard, Cheryl Louzado, Stephanie A. Nixon, Simone Shahid, Kortnee Tilson, Ciann Wilson, James Shaw   +11 more
doaj   +1 more source

IGF2 knockout reduces but does not abolish osteosarcoma growth in vitro and in vivo

FEBS Open Bio, EarlyView.
To test whether endogenous IGF2 promotes osteosarcoma growth, IGF2 was knocked out in Saos2 cells via CRISPR‐Cas9. KO cells showed reduced proliferation in vitro, and knockout xenografts in mice reached only ~25% of wild‐type tumor volume. Insulin‐like growth factor 2 (IGF2) is implicated in osteosarcoma, but direct functional evidence of its role is ...
Shun Yao, Marco Archetti
wiley   +1 more source

Sulfonylurea prescription patterns in elderly patients with type 2 diabetes mellitus: A comprehensive analysis of real‐world data from pharmacies in Japan

Journal of Diabetes Investigation
Aims/Introduction The study aim was to investigate sulfonylurea prescription patterns in elderly patients (age ≥65 years) with type 2 diabetes mellitus in Japan. Sulfonylurea use among older adults has been insufficiently examined, despite the associated
Michiko Yamazaki, Tohru Takebe, Masaya Hosokawa, Tomoya Saika, Yutaka Nakao, Shunya Ikeda, Masaya Sakamoto   +6 more
doaj   +1 more source

Type I interferons modulate autophagy to shape gemcitabine response in pancreatic cancer cells

FEBS Open Bio, EarlyView.
Type I interferons differentially modulate autophagy and the response of pancreatic cancer cells to gemcitabine. IFNα2b stimulates autophagic flux and protects cells from gemcitabine‐induced cell death, contributing to chemoresistance. In contrast, IFNβ1a inhibits autophagosome formation and enhances gemcitabine‐induced cell death, resulting in ...
Lucy E. Bonilla, Martín M. Ledesma, Santiago A. Behr, Matías A. Pibuel, María L. Palanek, Daniel H. Grasso, Maria N. Garcia, Juan Garona, Silvina L. Lompardía, Elida Álvarez, Daniela L. Papademetrio   +10 more
wiley   +1 more source

TRPML1 agonist ML‐SA5 attenuates pulmonary fibroblast activation by suppressing mTOR and restoring autophagic flux

FEBS Open Bio, EarlyView.
TGF‐β1 stimulation downregulates lysosomal channel TRPML1 in pulmonary fibroblasts. The TRPML1 agonist ML‐SA5 suppressed fibroblast‐to‐myofibroblast activation and collagen production. Mechanistically, ML‐SA5 inhibited mTOR phosphorylation, restored autophagic flux, and its effects were enhanced by rapamycin (mTOR inhibitor) and reversed by MHY1485 ...
Jiatong Yao, Xiaoting Kang, Lulu Meng, Shaoxuan Zhang, Qiujie Li, Jinyu Zhou, Mengyue Xue, Chu Li, Hua Zhu, Pengzhou Hang, Jing Zhao   +10 more
wiley   +1 more source

Dactolisib outperforms Rapamycin in potentiating apoptosis induced by XPO1, Bcl‐2 and Mcl‐1 blockade in preclinical glioblastoma models

FEBS Open Bio, EarlyView.
The PAM pathway and its impact on cellular metabolism. Color‐coded key symbols represent Rapamycin (R, orange, targeting mTOR) and Dactolisib (D, green, targeting PI3K/mTOR), indicating their sites of action. Created with BioRenders.com. Glioblastoma resists therapy through interconnected survival programs.
Kai Zhao, Leonie Meyer, Madita Braun, Katharina Otte, Celine Bitter, Maite Pawlik, Hartmann Raifer, Frederik Helmprobst, Axel Pagenstecher, Hans Urban, Michael C. Burger, Michael W. Ronellenfitsch, Joachim P. Steinbach, Jarmila Jedelská, Shamim Bagheri, Behrooz H. Yousefi, Pietro Di Fazio, Markus Luster, Andreas H. Mahnken, Andreas Neubauer, Andreas Burchert, Christopher Nimsky, Jörg W. Bartsch, Tillmann Rusch   +23 more
wiley   +1 more source

Patient and Physician Perspectives of Treatment Burden in Multiple Sclerosis

Neurology and Therapy
The number of disease-modifying therapies (DMTs) approved for the treatment of multiple sclerosis (MS) has greatly increased in recent decades, leading to higher treatment complexity.
Barry A. Singer, Dawn Morgan, Julie A. Stamm, Anita A. Williams   +3 more
doaj   +1 more source